Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | MAP4K3 | Q8IVH8 | 6/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29675739 | 0.92 | MET (0.49) | ALKCHRNB2CHRNA4IRAK4MAP4K3 | |
| Trifluoroacetic Acid SCHEMBL19065673 | 0.92 | MET (0.49) | ALKCHRNB2CHRNA4IRAK4MAP4K3 | |
| SCHEMBL19065271 | 0.89 | ALK (0.51) | ALKCHRNB2CHRNA4IRAK4NPY5R | |
| SCHEMBL19065254 | 0.85 | LRRK2 (0.45) | ALKCHRNB2CHRNA4IRAK4NPY5R | |
| Trifluoroacetic Acid SCHEMBL29675603 | 0.82 | IRAK4 (0.45) | ALKIRAK4NPY5RMET | |
| Trifluoroacetic Acid SCHEMBL19065679 | 0.82 | IRAK4 (0.45) | ALKIRAK4NPY5RMET | |
| SCHEMBL19065641 | 0.80 | NPY5R (0.53) | ALKPIM1NPY5R | |
| Trifluoroacetic Acid SCHEMBL19065555 | 0.79 | FGFR3 (0.43) | ALKIRAK4NPY5RMET | |
| Trifluoroacetic Acid SCHEMBL29675378 | 0.79 | FGFR3 (0.43) | ALKIRAK4NPY5RMET | |
| SCHEMBL19087046 | 0.78 | NPY5R (0.53) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | claimed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | claimed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | claimed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | claimed |
| EP-3400221-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2018-11-14 | — | — | EP | claimed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | claimed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | claimed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | ALK 1055/4885CHRNB2 2228/4885CHRNA4 2025/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | ALK 1055/4885CHRNB2 2228/4885CHRNA4 2025/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | ALK 1055/4885CHRNB2 2228/4885CHRNA4 2025/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | ALK 1055/4885CHRNB2 2228/4885CHRNA4 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.